Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8193769 | 0.83 | SMN1; SMN2 (0.42) | KDM4EMAPTIDO1ALDH1A1SLC6A2 | |
| SCHEMBL4181089 | 0.81 | IDO1 (0.58) | IDO1ALDH1A1SLC6A4CALM1 | |
| SCHEMBL27329 | 0.81 | IDO1 (0.58) | IDO1ALDH1A1SLC6A4CALM1 | |
| SCHEMBL8573606 | 0.80 | EPHX2 (0.52) | EPHX2ALDH1A1HPGD | |
| Methyl Alcohol SCHEMBL28311094 | 0.79 | IDO1 (0.56) | IDO1ALDH1A1SLC6A4CALM1 | |
| SCHEMBL1477048 | 0.79 | IDO1 (0.56) | IDO1ALDH1A1SLC6A4CALM1 | |
| Methoxymethane SCHEMBL28284584 | 0.79 | IDO1 (0.56) | IDO1ALDH1A1SLC6A4CALM1 | |
| SCHEMBL1475480 | 0.79 | IDO1 (0.56) | IDO1ALDH1A1SLC6A4CALM1 | |
| 3-Methoxyphenylacetonitrile SCHEMBL7387181 | 0.79 | PKM (0.48) | MAPTIDO1KMT2AALDH1A1HPGD | |
| Alcohol SCHEMBL2947640 | 0.77 | IDO1 (0.54) | IDO1ALDH1A1SLC6A4CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750009-B2 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-06 | — | — | US | disclosed |
| US-20060116373-A1 | Substituted pteridines for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116373-A1 | Substituted pteridines for the treatment of inflammatory diseases | LTC4S, TLR5, LTB4R2 | KDM4E 3119/4885MAPT 2694/4885IDO1 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.